Trial Profile
Transarterial Chemoembolization (TACE) With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma: a Multicenter Prospective Nonrandomized Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Ethiodized oil
- Indications Liver cancer
- Focus Therapeutic Use
- 31 Jul 2019 Planned End Date changed from 1 Oct 2018 to 1 Oct 2021.
- 31 Jul 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2021.
- 21 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.